---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-276070"
form_type: "8-K"
ticker: "LBRX"
cik: "0001691082"
company_name: "LB PHARMACEUTICALS INC"
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:18:03.268391+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# LB Pharmaceuticals appoints Kaya Pai Panandiker as Chief Commercial Officer

## Summary
- Effective Nov 10, 2025; Panandiker previously CCO at Neumora Therapeutics.
- She led commercial at Cerevel (acquired by AbbVie) and was GM Neuroscience at Lundbeck.
- Oversaw launches of REXULTI, TRINTELLIX, and ABILIFY MAINTENA (blockbuster sales).
- Will lead commercialization of lead candidate LB-102 for schizophrenia and bipolar depression.
- Company intends to grant her an inducement equity award outside its 2025 Equity Incentive Plan.

## SEC filing metadata
- accession: 0001193125-25-276070
- form_type: 8-K
- ticker: LBRX
- cik: 0001691082
- company_name: LB PHARMACEUTICALS INC
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1691082/000119312525276070/0001193125-25-276070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1691082/000119312525276070/d79831d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-276070
- JSON: https://secwatch.observer/filing/0001193125-25-276070.json
- Plain text: https://secwatch.observer/filing/0001193125-25-276070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.